Natixis Advisors LLC Has $239.62 Million Stock Position in AbbVie Inc. (NYSE:ABBV)

Natixis Advisors LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 5.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,213,411 shares of the company’s stock after buying an additional 60,157 shares during the period. Natixis Advisors LLC owned 0.07% of AbbVie worth $239,624,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new stake in AbbVie in the 1st quarter valued at $646,000. Quent Capital LLC lifted its stake in shares of AbbVie by 3.3% in the first quarter. Quent Capital LLC now owns 8,740 shares of the company’s stock valued at $1,592,000 after buying an additional 283 shares during the period. Strait & Sound Wealth Management LLC grew its position in AbbVie by 1.0% during the first quarter. Strait & Sound Wealth Management LLC now owns 9,267 shares of the company’s stock worth $1,552,000 after buying an additional 94 shares in the last quarter. Jacobi Capital Management LLC increased its stake in AbbVie by 2.1% during the first quarter. Jacobi Capital Management LLC now owns 32,430 shares of the company’s stock valued at $5,906,000 after acquiring an additional 669 shares during the period. Finally, Northern Capital Management Inc. raised its holdings in AbbVie by 6.7% in the 1st quarter. Northern Capital Management Inc. now owns 1,711 shares of the company’s stock valued at $312,000 after acquiring an additional 107 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABBV has been the subject of a number of recent research reports. Truist Financial increased their price objective on shares of AbbVie from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Morgan Stanley cut their price target on shares of AbbVie from $231.00 to $224.00 and set an “overweight” rating for the company in a research note on Tuesday. UBS Group upped their price objective on AbbVie from $195.00 to $200.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Guggenheim raised their target price on AbbVie from $212.00 to $221.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, Citigroup lowered their price target on AbbVie from $226.00 to $215.00 and set a “buy” rating on the stock in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $203.89.

AbbVie Stock Down 2.7 %

Shares of NYSE:ABBV opened at $164.99 on Friday. The company has a 50 day moving average price of $192.04 and a two-hundred day moving average price of $180.78. The company has a market capitalization of $291.56 billion, a PE ratio of 57.26, a PEG ratio of 2.07 and a beta of 0.63. AbbVie Inc. has a 52 week low of $137.05 and a 52 week high of $207.32. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. During the same quarter last year, the business posted $2.95 EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. Analysts forecast that AbbVie Inc. will post 10.95 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Wednesday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.55. AbbVie’s dividend payout ratio is 215.28%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.